Xylem (XYL) is back in focus after earnings and guidance, as the company paired higher full year 2025 revenue and profit with cautious 2026 growth expectations and a completed Evoqua integration.

Despite solid 2025 results and a higher dividend, investor caution around Xylem’s modest 2026 revenue guidance and pullback in China has weighed on sentiment. The 30 day share price return shows a 12.35% decline and the year to date share price return shows a 6.58% decline, even as the 5 year total shareholder return of 36.09% points to a much stronger long term picture.

If this mix of earnings strength and market hesitation has your attention, you might also want to scan our list of 25 power grid technology and infrastructure stocks for more grid focused opportunities tied to infrastructure spend.

With Xylem trading at $128.09, sitting at an estimated 18% discount to some intrinsic value models and roughly 24% below aggregated analyst targets, you have to ask: is this a reset that opens a buying window, or is the market already bracing for slower growth?

Most Popular Narrative: 19.1% Undervalued

With Xylem at $128.09 against a narrative fair value of $158.41, the gap comes down to how you view its future cash generation and margins.

The company's operational simplification and implementation of the 80/20 model is already delivering record on-time performance, increased productivity, and measurable margin improvements, signaling sustainable cost efficiencies and enhanced net margins moving forward.

Read the complete narrative. Read the complete narrative.

If you want to see what drives that higher fair value, look at the earnings path, the margin trajectory, and the valuation multiple the narrative assumes.

Result: Fair Value of $158.41 (UNDERVALUED)

However, there are real swing factors here, including weaker orders from China and any delay in government-backed water infrastructure funding in key regions.

Build Your Own Xylem Narrative

If you look at the numbers and reach a different conclusion, or simply prefer to test your own assumptions, you can build a custom view for Xylem in just a few minutes using our tools, Do it your way.

A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Xylem.

Looking for more investment ideas?

If Xylem has sharpened your interest, do not stop here. Use the Simply Wall St Screener to line up more opportunities that actually fit your approach.

• Target value and quality together by reviewing our list of 54 high quality undervalued stocks that pair supportive fundamentals with pricing that may appeal to long term investors.
• Prioritise capital strength by scanning the solid balance sheet and fundamentals stocks screener (44 results) if you want companies that place balance sheet resilience near the top of the list.
• Spot potential market mispricing early by checking the screener containing 24 high quality undiscovered gems that other investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.